Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders
Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders
Company Info
Company news
Thu, 26 Aug 2021 07:00:00 GMT
Neurogastrx assembles ex-Ironwood team with $60M to take on jam-packed gastrointestinal market - Fierce Biotech
Wed, 16 Oct 2024 07:00:00 GMT
Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication - Yahoo Finance
Tue, 08 Jun 2021 07:00:00 GMT
Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S. - PR Newswire
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.